{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-079042","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.773143+00:00","generated_at":"2026-05-17T12:27:12.464595+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioXcel receives positive FDA preliminary comments ahead of pre-sNDA meeting","bullets":["Positive preliminary FDA meeting comments received August 14, 2025.","Pre-sNDA meeting scheduled for August 20, 2025 to align on sNDA submission format and content.","Company evaluating feedback and plans to provide update next week."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-079042","json":"https://secwatch.observer/filing/0001104659-25-079042.json","markdown":"https://secwatch.observer/filing/0001104659-25-079042.md","text":"https://secwatch.observer/filing/0001104659-25-079042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925079042/0001104659-25-079042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925079042/tm2523368d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:27:12.464595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}